Polyene phosphatidylcholine for liver injury after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a medicine called polyene phosphatidylcholine can help protect the liver from damage after surgery for liver cancer. It is for people who are having a specific type of keyhole surgery to remove part of the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a single liver cancer tumor (HCC) that is less than 10 cm and has not spread.
- You are between 18 and 80 years old and have a BMI between 18.5 and 28.
- You are scheduled for a specific type of liver surgery (anatomical laparoscopic resection) that may involve blocking blood flow to the liver for short periods.
- You have not had a liver-damaging drug or treatment within the last 2 weeks, and no other liver cancer treatments like TACE or systemic therapy within the last 6 months or 4 weeks.
- You do not have severe health problems like heart disease, kidney disease, or a bleeding disorder, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.